Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Core Viewpoint - Rezolute, Inc. is actively participating in the BTIG Virtual Biotechnology Conference, indicating its commitment to engaging with investors and stakeholders in the biotechnology sector [1][2]. Company Overview - Rezolute, Inc. is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI) [3]. - The company's antibody therapy, ersodetug, aims to treat all forms of HI and has demonstrated significant benefits in both clinical trials and real-world applications for congenital HI and tumor HI [3].